natgillin/translations-raw huggingface dataset:
The use of claim 1 or 2, wherein said powder composition further comprises a powder dyeing agent. 
Kompozicija za uporabu prema patentnom zahtjevu 1 ili 2, naznačena time što navedena kompozicija u obliku praška dalje sadrži sredstvo za bojenje praška.
The use of claim 4, wherein said powder composition is dissolved in an aqueous medium until a concentration of at least 250 ppm of chlorine is obtained. 
Kompozicija za uporabu prema patentnom zahtjevu 4, naznačena time što je navedena kompozicija u obliku praška otapana u vodenom mediju sve dok nije dobijena koncentracija od najmanje 250 ppm klora.
The use of any one of claims 1-5, wherein said powder composition consists of: 
Kompozicija za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačena time što se navedena kompozicija u obliku praška sastoji od:
to 4% by weight of sodium or potassium carbonate, and 
do 4 težinskih % natrijeva ili kalijeva karbonata, i
to 4% by weight of dyeing agent. 
do 4 težinskih % sredstva za bojenje.
from 10 to 40% by weight, on the total composition weight, of at least one chlorinated organic compound selected from the group consisting of chlorinated isocyanuric acid or its salts, aromatic chloro-sulphonamide or its salts, and mixtures thereof, 
od 10 do 40 težinskih %, od ukupne težine kompozicije, najmanje jedan klorirani organski spoj koji je izabran iz grupe koju čine klorirana izocijanurna kiselina ili njene soli, aromatični kloro-sulfonamid ili njegove soli, i njihove smjese,
from 0 to 6% by weight of an inorganic carbonate, and veterinarily acceptable adjuvants and/or excipients. 
od 0 do 6 težinskih % neorganskog karbonata, i veterinarski prihvatljive adjuvante i/ili inertne punitelje.
The composition of claim 8, wherein said chlorinated organic compound is selected from the group consisting of sodium trichloroisocyanurate, sodium dichloroisocyanurate, Chloramine T and mixtures thereof. 
Kompozicija prema patentnom zahtjevu 8, naznačena time što je navedeni klorirani organski spoj izabran iz grupe koju čine natrijev trikloroizocijanurat, natrijev dikloroizocijanurat, kloramin T i njihove smjese.
A binding molecule according to claim 1, wherein said binding molecule also has neutralizing activity against an influenza virus comprising HA of the H1 subtype, such as H1N1, and preferably wherein said binding molecule also has neutralizing activity against an influenza virus comprising HA of the H2, H6 and/or H9 subtype. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 1, naznačeni time da navedeno antitijelo ili njegov dio koji veže antigen također ima neutralizirajuću aktivnost protiv virusa influence koji sadrži HA podvrste H1, kao H1N1, te poželjno time da navedeno antitijelo ili njegov dio koji veže antigen također ima neutralizirajuću aktivnost protiv virusa influence koji sadrži HA podvrste H2, H6 i/ili H9.
A binding molecule according to claim 7, wherein said influenza virus strain that is associated with a pandemic outbreak is selected from the group consisting of: H1N1, H5N1, H5N2, H5N8, H5N9, an H2-based strain, and H9N2. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 6, naznačeni time da je navedeni soj virusa influence koji je povezan sa izbijanjem pandemije odabran iz skupine koja sadrži: H1N1, H5N1, H5N2, H5N8, H5N9, soj na osnovi H2, i H9N2.
Packaging system having a bottle (b) comprising a pharmaceutical composition to be transferred in a container holding a liquid for intravenous infusion, characterized in that 
Sustav pakiranja koji ima bočicu (b) što sadrži farmaceutski sastav koji se prenosi u spremnik gdje se drži tekućina za intravenoznu infuziju, naznačen time, da
said pharmaceutical composition comprises 5 mg of tacrolimus dissolved in 1 ml of solvent composed of 200 mg of polyoxyethylenated hydrogenated castor oil (HCO-60) and ethanol q.s. to 1 ml. 
navedeni farmaceutski sastav sadrži 5 mg takrolimusa, otopljenog u 1 ml otapala sastavljenog od 200 mg polioksietiliranog hidriranog ricinusovog ulja (HCO-60) i etanola dopunjenog do 1 ml.
Packaging system according to claim 1, characterized in that said ethanol is selected from absolute ethanol and anhydrous ethanol USP 80.0 % v/v. 
Sustav pakiranja prema patentnom zahtjevu 1, naznačen time, da je navedeni etanol odabran između apsolutnog etanola i bezvodnog etanola USP 80,0% (vol.)
Packaging system according to claim 2, characterised in that said bottle has a capacity between 6 and 9 ml. 
Sustav pakiranja prema patentnom zahtjevu 2, naznačen time, da navedena bočica ima zapreminu između 6 i 9 ml.
Packaging system according to claim 3, characterised in that said bottle has a capacity of 7 ml. 
Sustav pakiranja prema patentnom zahtjevu 3, naznačen time, da navedena bočica ima zapreminu od 7 ml.
Kit for the parenteral administration of drugs with an intravenous approach which comprises at least: 
Komplet za parenteralno davanje lijekova intravenoznim putem koji sadrži barem:
a container holding a fluid for intravenous infusion made of collapsible material; 
spremnik za držanje fluida za intravenoznu infuziju izrađen od složivog materijala;
a dosage unit comprising at least one pharmaceutical composition in liquid form to be parenterally administered; 
jedinicu doziranja koja sadrži barem jedan farmaceutski sastav u tekućem obliku za parenteralno davanje;
a means for transferring the pharmaceutical composition from the dosage unit (b) to the container (a); 
sredstvo za prijenos farmaceutskog sastava iz jedinice doziranja (b) u spremnik (a);
Kit according to claim 5 characterised in that said means for transferring the pharmaceutical composition from the dosage unit (b) to the container (a) is a connector with at least two spikes. 
Komplet prema patentnom zahtjevu 5, naznačen time, da navedeno sredstvo za prijenos farmaceutskog sastava iz jedinice doziranja (b) u spremnik (a) jest spojni komad s barem dva probojna šiljka.
Kit according to one of the claims 5 or 6 wherein the dosage unit is in the form of a bottle with a capacity of about 7 ml, comprising at least one pharmaceutical composition composed of 5 mg of tacrolimus dissolved in 1 ml of solvent composed of 200 mg of polyoxyethylenated hydrogenated castor oil (HCO-60) and ethanol q.s. to 1 ml, a means for transferring the pharmaceutical composition from the dosage unit (b') to the container (a). 
Komplet prema jednom od patentnih zahtjeva 5 ili 6, naznačen time, da je jedinica doziranja u obliku bočice zapremine od oko 7 ml, da sadrži barem jedan farmaceutski sastav sastavljen od 5 mg takrolimusa otopljenog u 1 ml otapala sastavljenog od 200 mg polioksietiliranog hidriranog ricinusovog ulja (HCO-60) i etanola dopunjenog do 1 ml, te sredstvo (c) za prenošenje farmaceutskog sastava iz jedinice doziranja (b') u spremnik (a).
Kit according to claim 7 characterised in that said pharmaceutical composition also comprises from 0.1 to 0.5 mg of citric acid. 
Komplet prema patentnom zahtjevu 7, naznačen time, da navedeni farmaceutski sastav također sadrži od 0,1 do 0,5 mg limunske kiseline.
the container (a) is a collapsible container for intravenous infusion containing 500 ml of a saline solution of 0.9% sodium chloride, coupling and butterfly needle, the whole being made of PE; 
je spremnik (a) složivi spremnik za intravenoznu infuziju koji sadrži 500 ml fiziološke otopine s 0,9% natrijevog klorida, te priključak i leptirastu kanilu, u cjelini izrađene od PE;
the means (c) is a connector with at least two perforating spikes; and further comprising 
je sredstvo (c) spojni komad s barem dva probojna šiljka; i da nadalje sadrži
a pair of disposal gloves for pharmaceutical use; 
par rukavica za jednokratnu farmaceutsku uporabu;
Pasireotide or a pharmaceutically acceptable salt thereof for use according to claim 1 for the treatment of endogenous hyperinsulinemic hypoglycemia caused by one or more drugs selected from i) alcohol, ii) Cibezoline, Gatifloxin, Pentamidine, Quinine, Indomethacin, Glucagon (during endoscopy), iii) Chloroquineoxaline sulfonamide, Artesunate/artemisin/artemether, IGF-1, Lit-ium, Propoxyphene/dextropropoxyphene, or iv) Angiotensin converting enzyme inhibitors, Angiotensin receptor antagonists, beta-Adrenergic receptor antagonists, Levofloxacin, Mifepristone, Disopyramide, Trimehtoprim-sulfamethoxazole, Heparin, 6-mercaptopurine. 
Pasireotid ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 1, naznačen time, da je za liječenje endogene hiperinzulinemijske hipoglikemije uzrokovane s jednim ili više narkotika odabranih od sljedećih: i) alkohol, ii) cibezolin, gatifloxin, pentamidin, kinin, indometazin, glukagon (za vrijeme endoskopije), iii) klorokinooksalin sulfonamid, artezunat/artemizinin/artemeter, IGF-1, litij, propoksifen/dekstropropoksifen ili iv) inhibitori enzima koji pretvaraju angiotenzin, antagonisti receptora angiotenzina, antagonisti receptora beta-andrenergena, levofloksacin, mifepriston, dizopiramid, trimetoprim-sulfametoksazol, heparin, 6-merkaptopurin.
A pharmaceutical composition for use in treatment of endogenous hyperinsulinemic hypoglycemia, wherein the wherein the endogenous hyperinsulinemic hypoglycemia is not caused by insulinoma, comprising pasireotide or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable diluents or carriers therefore. 
Farmaceutski sastav, naznačen time, da se upotrebljava za liječenje endogene hiperinzulinemijske hipoglikemije, gdje endogena hiperinzulinemijska hipoglikemija nije uzrokovana inzulinomom, pri čemu farmaceutski sastav obuhvaća pasireotid ili njegovu farmaceutski prihvatljivu sol, zajedno s jednim ili više farmaceutski prihvatljivih razrjeđivača ili nosača.
Composition according to claim 1 characterized in that it comprises one or more additional substances with antacid activity chosen from: Al(OH)3, Mg(OH)2, MgO, magaldrate, carbonates or bicarbonates of alkali or alkaline-earth metals, simethicone, salts of alginic acid which enable formation of gelatinous foams, hydrolyzed or non-hydrolyzed chitins, saccharide polymers, glucomannans, PEG, cimetidine and similar H2 blockers, misoprostol and proton pump inhibitors (PPI). 
Smjesa prema zahtjevu 1 naznačena time što sadrži jednu ili više dodatnih tvari s djelovanjem protiv kiseline (antacidni učinak) izabranih između: Al(OH)3, Mg(OH)2, MgO, magaldrat, karbonati ili bikarbonati alkalijskih ili zemno-alkalijskih metala, simetikon, soli alginske kiseline koje omogućuju stvaranje želatinoznih pjena, hidrolizirani ili nehidrolizirani hitini, saharidni polimeri, glukomanan, PEG, cimetidin i slični H2 blokatori, misoprostol i inhibitori protonske pumpe (PPI).
Composition according to claim 4 characterized in that said polar phospholipids have a higher than 97% degree of acetone insolubility. 
Smjesa prema zahtjevu 4 naznačena time što polarni fosfolipidi imaju stupanj netopljivosti u acetonu veći od 97%.
Composition according to claim 1 characterized by containing sucralfate and phospholipids in a weight ratio from about 1:0.5 to about 1:2. 
Smjesa prema zahtjevu 1 naznačena time što su sukralfat i fosfolipidi sadržani u masenom omjeru od oko 1:0.5 do oko 1:2.
Composition according to claim 1 characterized by containing sucralfate and phospholipids in a weight ratio of 1:1. 
Smjesa prema zahtjevu 1 naznačena time što su sukralfat i fosfolipidi sadržani u masenom omjeru od 1:1.
Use of sucralfate in combination with phospholipids for the preparation of a composition to be administered orally for the treatment of gastrointestinal irritation disorders such as gastric ulcers, duodenal ulcers, acute gastritis, symptomatic chronic gastritis, gastropathy related to anti-inflammatories, reflux esophagitis, for improving palatability. 
Uporaba sukralfata u kombinaciji s fosfolipidima za pripremu smjese koja će se davati oralnim putem za liječenje iritabilnih probavnih poremećaja kao što je čir na želucu, čir na dvanaesniku, akutni gastritis, simptomatski kronični gastritis, gastropatija povezana s protu-upalnim lijekovima, refluksni ezofagitis, a radi poboljšanja okusa.
Use according to claim 11, wherein the said composition is to be administered orally for the treatment of gastrointestinal irritation disorders and to synergistically improve the antiulcer activity of sucralfate. 
Uporaba prema zahtjevu 11, gdje je ta smjesa namijenjena oralnoj primjeni za liječenje iritabilnih probavnih poremećaja i za sinergijsko poboljšanje učinka sukralfata protiv čira.
Use according to claim 15 characterized in that said phospholipids have a higher than 97% degree of acetone insolubility. 
Uporaba prema zahtjevu 15 naznačena time što polarni fosfolipidi imaju stupanj netopljivosti u acetonu veći od 97%.
R9, at each occurrence, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R8a, and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, alkenil, alkinil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10, at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 R10a, and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kad se pojavljuje, je nezavisno izabran između alkil, alkenil, alkinil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
the term "alkyl" as used herein refers to both branched and straight-chain saturated aliphatic hydrocarbon groups containing 1 to 10 carbons in the normal chain, and is optionally substituted with from 1 to 4 substituents selected from F, Br, Cl, I, CF3, alkyl, alkoxy, aryl, aryloxy, aryl or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, alkylthio, arylalkylthio, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl, and/or alkylthio; 
pojam "alkil", kako se ovdje koristi, odnosi se i razgranate i ravnolančane zasićene alifatske ugljikovodične skupine koje sadrže 1 do 10 ugljika u normalnom lancu, i po izboru je supstituiran s od 1 do 4 supstituenta izabrana između F, Br, Cl, I, CF3, alkil, alkoksi, aril, ariloksi, aril ili diaril, arilalkil, arilalkiloksi, alkenil, cikloalkil, cikloalkilalkil, cikloalkilalkiloksi, amino, hidroksi, hidroksialkil, acil, heteroaril, heteroariloksi, heteroarilalkil, heteroarilalkoksi, ariloksialkil, alkiltio, arilalkiltio, ariloksiaril, alkilamido, alkanoilamino, arilkarbonilamino, nitro, cijano, tiol, haloalkil, trihaloalkil, i/ili alkiltio;
the term "alkenyl" as used herein refers to straight or branched chain radicals of 2 to 12 carbons in the normal chain, which contains one to six double bonds in the normal chain, and is optionally substituted with 1 to 4 substituents selected from halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol, alkylthio, and/or any of the alkyl substituents set out herein; 
pojam "alkenil", kako se ovdje koristi, odnosi se na ravne ili razgranate lančane radikale s 2 do 12 ugljika u normalnom lancu, koji sadrži jednu do šest dvostrukih veza u normalnom lancu, i po izboru je supstituiran s 1 do 4 supstituenta izabrana između halogen, haloalkil, alkil, alkoksi, alkenil, alkinil, aril, arilalkil, cikloalkil, amino, hidroksi, heteroaril, cikloheteroalkil, alkanoilamino, alkilamido, arilkarbonil-amino, nitro, cijano, tiol, alkiltio, i/ili bilo koji od alkil supstituenata ovdje navedenih;
the term "alkynyl" as used herein refers to straight or branched chain radicals of 2 to 12 carbons in the normal chain, which includes one triple bond in the normal chain, and is optionally substituted with 1 to 4 substituents selected from halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or any of the alkyl substituents set out herein; 
pojam "alkinil", kako se ovdje koristi, odnosi se na ravne ili razgranate lančane radikale s 2 do 12 ugljika u normalnom lancu, koji uključuje jednu trostruku vezu u normalnom lancu, i po izboru je supstituiran s 1 do 4 supstituenta izabrana između halogen, haloalkil, alkil, alkoksi, alkenil, alkinil, aril, arilalkil, cikloalkil, amino, heteroaril, cikloheteroalkil, hidroksi, alkanoilamino, alkilamido, arilkarbonilamino, nitro, cijano, tiol, i/ili alkiltio, i/ili bilo koji od alkil supstituenata ovdje navedenih;
the term "cycloalkyl" as employed herein refers to saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings containing a total of 3 to 15 carbons forming the ring and which may be fused to 1 or 2 aromatic rings halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, and/or alkylthio, and/or any of the substituents for alkyl; 
pojam "cikloalkil", kako se ovdje koristi, odnosi se na zasićene ili djelomično nezasićene (sadrži 1 ili 2 dvostruke veze) cikličke ugljikovodične skupine koje sadrže 1 do 3 prstena koji sadrže ukupno 3 do 15 ugljika koji formiraju prsten i koji mogu biti fuzionirani za 1 ili 2 aromatska prstena, halogen, alkil, alkoksi, hidroksi, aril, ariloksi, arilalkil, cikloalkil, alkilamido, alkanoilamino, okso, acil, arilkarbonilamino, amino, nitro, cijano, tiol, i/ili alkiltio, i/ili bilo koji supstituent za alkil;
the term "heteroaryl" as employed herein refers to a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring containing carbon atoms and from 1 to 4 heteroatoms independently selected from N, O and S. 
pojam "heteroaril", kako se ovdje koristi, odnosi se na stabilni 5-eročlani do 7-eročlani monociklički ili biciklički ili 7-eročlani do 10-eročlani biciklički heterociklički aromatski prsten koji sadrži atome ugljika i od 1 to 4 heteroatoma nezavisno izabrana između N, O i S.
R9, at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R8a, and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 R10a, and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kad se pojavljuje, je nezavisno izabran između alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R8a, and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and heterocyclyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and heterocyclyl may each be optionally substituted with 0-3 R10a, and the heteroaryl, heteroarylalkyl and heterocyclyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kad se pojavljuje, je nezavisno izabran između alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil i heterociklil, gdje cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil i heterociklil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril, heteroarilalkil i heterociklil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and heterocyclyl may each be optionally substituted with 0-5 R8a, and the heteroaryl, heteroarylalkyl and heterocyclyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil i heterociklil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil i heterociklil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil i heterociklil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
A pharmaceutical composition comprised of a therapeutically effective amount of a compound of any one of claims 1 to 11, or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier. 
Farmaceutska smjesa koja se sastoji od terapijski učinkovite količine spoja prema bilo kojem od zahtjeva 1 do 11, ili enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, i po izboru farmaceutski prihvatljivi nosač.